Moreover, studies in ovarian and prostate cancer have revealed multiple-gene (e.g., BRCA1 and BRCA2) reversion mutations merely identified in progressive tumor tissues, which lead to the restoration of DNA repair function and acquired drug resistance. This evidence concerns the gene BRCA1 and prostate cancer.